141 related articles for article (PubMed ID: 36992294)
1. Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants.
Alcantara MC; Higuchi Y; Kirita Y; Matoba S; Hoshino A
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992294
[TBL] [Abstract][Full Text] [Related]
2. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.
Touret F; Giraud E; Bourret J; Donati F; Tran-Rajau J; Chiaravalli J; Lemoine F; Agou F; Simon-Lorière E; van der Werf S; de Lamballerie X
iScience; 2023 Apr; 26(4):106413. PubMed ID: 36968074
[TBL] [Abstract][Full Text] [Related]
3. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
mBio; 2024 Jul; ():e0090724. PubMed ID: 38953636
[TBL] [Abstract][Full Text] [Related]
4. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
[TBL] [Abstract][Full Text] [Related]
5. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
[TBL] [Abstract][Full Text] [Related]
6. Digital PCR Discriminates between SARS-CoV-2 Omicron Variants and Immune Escape Mutations.
Holland SC; Holland LA; Smith MF; Lee MB; Hu JC; Lim ES
Microbiol Spectr; 2023 Aug; 11(4):e0525822. PubMed ID: 37306573
[TBL] [Abstract][Full Text] [Related]
7. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
[TBL] [Abstract][Full Text] [Related]
8. Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants.
Nagasawa N; Kimura R; Akagawa M; Shirai T; Sada M; Okayama K; Sato-Fujimoto Y; Saito M; Kondo M; Katayama K; Ryo A; Kuroda M; Kimura H
Microorganisms; 2023 Sep; 11(9):. PubMed ID: 37764181
[TBL] [Abstract][Full Text] [Related]
9. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
10. Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.
Di H; Pusch EA; Jones J; Kovacs NA; Hassell N; Sheth M; Lynn KS; Keller MW; Wilson MM; Keong LM; Cui D; Park SH; Chau R; Lacek KA; Liddell JD; Kirby MK; Yang G; Johnson M; Thor S; Zanders N; Feng C; Surie D; DeCuir J; Lester SN; Atherton L; Hicks H; Tamin A; Harcourt JL; Coughlin MM; Self WH; Rhoads JP; Gibbs KW; Hager DN; Shapiro NI; Exline MC; Lauring AS; Rambo-Martin B; Paden CR; Kondor RJ; Lee JS; Barnes JR; Thornburg NJ; Zhou B; Wentworth DE; Davis CT
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793756
[TBL] [Abstract][Full Text] [Related]
11. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
[TBL] [Abstract][Full Text] [Related]
12. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Ao D; He X; Hong W; Wei X
MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
[TBL] [Abstract][Full Text] [Related]
13. Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.
Bhattacharya M; Chatterjee S; Lee SS; Dhama K; Chakraborty C
Drug Resist Updat; 2023 Nov; 71():101008. PubMed ID: 37757651
[TBL] [Abstract][Full Text] [Related]
14. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
15. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
[TBL] [Abstract][Full Text] [Related]
16. Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.
Shah M; Woo HG
Front Mol Biosci; 2023; 10():1236617. PubMed ID: 37828918
[TBL] [Abstract][Full Text] [Related]
17. AlphaFold2-Enabled Atomistic Modeling of Structure, Conformational Ensembles, and Binding Energetics of the SARS-CoV-2 Omicron BA.2.86 Spike Protein with ACE2 Host Receptor and Antibodies: Compensatory Functional Effects of Binding Hotspots in Modulating Mechanisms of Receptor Binding and Immune Escape.
Raisinghani N; Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G
J Chem Inf Model; 2024 Mar; 64(5):1657-1681. PubMed ID: 38373700
[TBL] [Abstract][Full Text] [Related]
18. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
19. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
Nat Commun; 2023 Feb; 14(1):824. PubMed ID: 36788246
[TBL] [Abstract][Full Text] [Related]
20. Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies.
Guo H; Jiang J; Shen S; Ge X; Fan Q; Zhou B; Cheng L; Ju B; Zhang Z
iScience; 2023 Apr; 26(4):106283. PubMed ID: 36925722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
